ADPT Adaptive Biotechnologies Corp

Adaptive Biotechnologies announced that its 70%-owned subsidiary, Digital Biotechnologies, Inc., has commenced a Series A Preferred Stock financing round with anticipated proceeds of up to $15 million. Adaptive expects to maintain nearly 50% ownership and continue consolidating Digital Biotechnologies' financial results. This development follows strong Q3 2025 financial performance, strategic partnerships with Pfizer, and an "Overweight" rating from Piper Sandler despite increased market competition.

Adaptive Biotechnologies announced a Series A financing round for its subsidiary, Digital Biotechnologies, with an initial closing achieved. The round is expected to generate up to $15 million in proceeds, and Adaptive Biotechnologies anticipates retaining nearly 50% ownership while consolidating Digital Biotechnologies' results into its own financials.

Francis Lo, Chief People Officer at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 4,394 shares of common stock for approximately $76,895 and exercised options to acquire the same number of shares. The company has shown significant growth with a 178.57% year-to-date return and strong revenue growth. Adaptive Biotechnologies also reported a strong Q3 2025 performance and announced non-exclusive agreements with Pfizer.

Adaptive Biotechnologies (ADPT) has recently secured two non-exclusive deals with Pfizer, focusing on T-cell receptor discovery and AI-driven drug discovery for rheumatoid arthritis. This follows a significant rerating for ADPT, with a 181% year-to-date share price return. While a "narrative" valuation suggests the stock is 11% undervalued, a "revenue multiples" perspective indicates it is currently overvalued compared to industry peers.

Adaptive Biotechnologies (ADPT) saw a 10.1% rise in its stock after announcing two non-exclusive agreements with Pfizer. These collaborations involve applying Adaptive's T-cell receptor discovery platform to rheumatoid arthritis and licensing its TCR-antigen binding dataset for Pfizer's AI-driven drug discovery, with potential milestones up to US$890 million. The deals emphasize the commercial value of Adaptive's immune repertoire data and offer a new perspective on its investment narrative amid ongoing profitability challenges.

New options for Adaptive Biotechnologies (ADPT) for February 2026 expiration have started trading, with BNK Invest highlighting particular put and call contracts. A put contract at the $15.00 strike price offers a potential 0.67% return if it expires worthless, while a covered call strategy at the $17.50 strike price could yield a 6.84% return. The article details potential returns and risks for investors considering these option strategies.